Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) from a sell rating to a hold rating in a report issued on Monday morning.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

Several other research analysts also recently weighed in on the stock. William Blair began coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued an outperform rating and a $46.00 target price for the company. Barclays PLC began coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued an overweight rating and a $30.00 target price for the company. Piper Jaffray Companies began coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued an overweight rating and a $21.00 target price for the company. Morgan Stanley began coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, May 31st. They issued an overweight rating for the company. Finally, Needham & Company LLC began coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They issued a buy rating and a $30.00 target price for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $31.75.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 35.15 on Monday. The stock’s 50 day moving average is $25.97 and its 200 day moving average is $24.54. Biohaven Pharmaceutical Holding Co has a 1-year low of $17.00 and a 1-year high of $36.55. The company’s market cap is $1.26 billion.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/biohaven-pharmaceutical-holding-co-ltd-bhvn-raised-to-hold-at-zacks-investment-research/1533388.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.